Immunoglobulin Therapy

Phase 3Small molecule

Roche

Immunoglobulin Therapy is one of 66 small molecule programs targeting Cardiomyopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiomyopathyActive, not recruiting

Intracranial HemorrhageActive, not recruiting

COVID-19Active, not recruiting

CardiomyopathyPhase 1

Active, not recruiting

Intracranial HemorrhagePhase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Immunoglobulin Therapy

Roche

Phase 3

1 2

Calciferol

Alnylam Pharmaceuticals

Preclinical

—3

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Statin

Bristol-Myers Squibb

Preclinical

1 7

Selenium

SSWOG Cancer Research Network

Preclinical

1 8

Tpa

UUniversity of Florida

Preclinical

1 9

Other Tkis

Bayer

Preclinical

1 10

Pfizer-Biontech COVID-19 MRNA Vaccine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiomyopathy1 trial

IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load

Unknown status·MMaastricht University Medical Center·Phase 1·NCT00659386·40 enrolled

Efficacy1 trial

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Withdrawn· Roche logo

Roche·Phase 3·NCT05494619

COVID-191 trial

Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial

Unknown status·UUniversity of Health Sciences Lahore·Phase 3·NCT04548557·60 enrolled

Intracranial Hemorrhage1 trial

Intravenous Immunoglobulin for Acute Intracranial Hemorrhage

Unknown status·WWei Wang·Phase 2·NCT02782897·60 enrolled

Hematopoietic and Lymphoid Cell Neoplasm1 trial

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Terminated·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04438382·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Immunoglobulin Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunoglobulin Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunoglobulin Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Immunoglobulin Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiomyopathy1 trial

Efficacy1 trial

COVID-191 trial

Intracranial Hemorrhage1 trial

Hematopoietic and Lymphoid Cell Neoplasm1 trial

References

Drug Info

Quick Facts

Related News